Reports - Adeno-Associated Virus (AAV) Gene Therapy Market
HealthcareAdeno-Associated Virus (AAV) Gene Therapy Market
Adeno-Associated Virus (AAV) Gene Therapy Market Size & Share | Growth Analysis 2035 by Types (Luxturna, Zolgensma, Others) by Applications (Central Nervous System Diseases, Ocular Diseases, Liver-directed Diseases, Other Hereditary Diseases
Industry Leaders Trust Us For Actionable Intelligence
Table of Contents
Chapter 1 Executive Dashboard
1. Strategic Imperatives
Chapter 2 Premium Insights
1. Top 3 Trends to Watch
2. Demand and Supply Trends
3. Top 3 Strategies Followed by Major Players
4. Top 3 Predictions by Vantage Market Research
5. Top Investment Pockets
6. Insights from Primary Respondents
Chapter 3 Global Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. Global Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. Global Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. Global Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
5. Global Adeno-Associated Virus (AAV) Gene Therapy Market - by region
5.1. North America
5.2. Europe
5.3. Asia Pacific
5.4. Latin America
5.5. Middle East & Africa
6. Market comparative analysis
Chapter 4 North America Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. North America Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. North America Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. North America Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
Chapter 5 Europe Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. Europe Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. Europe Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. Europe Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
Chapter 6 Asia Pacific Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. Asia Pacific Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. Asia Pacific Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. Asia Pacific Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
Chapter 7 Latin America Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. Latin America Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
Chapter 8 Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market - Segment Analysis
1. Overview
2. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market, 2020 - 2032 (USD Million)
3. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market - by Types
3.1. By Luxturna
3.2. By Zolgensma
3.3. By Others
4. Middle East & Africa Adeno-Associated Virus (AAV) Gene Therapy Market - by Applications
4.1. By Central Nervous System Diseases
4.2. By Ocular Diseases
4.3. By Liver-directed Diseases
4.4. By Other Hereditary Diseases
Chapter 9 Key Market Dynamics
1. Introduction
2. Market Drivers
3. Market Restraints
4. Market Opportunities
5. Porter's Five Forces Analysis
6. PEST Analysis
7. Regulatory Landscape
8. Technology Landscape
9. Regional Market Trends
Chapter 10 COVID 19 Impact Analysis
1. Key strategies undertaken by companies to tackle COVID-19
2. Short term dynamics
3. Long term dynamics
Chapter 11 Marketing Strategy Analysis
1. Marketing Channel
2. Direct Marketing
3. Indirect Marketing
4. Marketing Channel Development Trends
Chapter 12 Competitive Landscape
1. Competition Matrix - 2021
2. Company Market Share Analysis - 2021
3. Key Company Activities, 2018 - 2021
4. Strategic Developments - Heat Map Analysis
5. Company Offering Evaluation
6. Company Regional Presence Evaluation
Chapter 13 Company Profiles
1. Creative Biolabs
2. Affinia Therapeutics
3. Spark Therapeutics
4. AGC Biologics
5. StrideBio
6. SIRION Biotech
7. Neurophth Biotechnology
8. Belief BioMed
9. BiBo Biopharma Engineering Co. Ltd.
10. Beihai Kangcheng
11. PackGene Biotech
12. Sarepta Therapeutics
13. Carbon BioSciences
14. Kelonia Therapeutics
15. Roche
16. Remedium Bio
Chapter 14 Key Primary Respondents - VERBATIM
Chapter 15 Discussion Guide
Chapter 16 Customization Offered
Chapter 17 Annexure
Chapter 18 List of Figures
Chapter 19 List of Tables
Chapter 20 List of Abbreviations
FAQ‘s
Related Reports
Contact
Toll Free Number+1 (877) 462-2282
© 2025 Vantage Market Research. All right reserved
Secured By